KIAA1217: A Potential Drug Target and Biomarker (G56243)

Target Name: KIAA1217

NCBI ID: G56243

KIAA1217

KIAA1217: A Potential Drug Target and Biomarker

Introduction

KIAA1217 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a key regulator of the cell cycle, and its levels have been linked to the development and progression of many diseases, including cancer. In recent years, the research team has discovered the expression levels of KIAA1217 in a variety of diseases, including cancer, neurological diseases, and metabolic diseases. In addition, KIAA1217 was also found to be associated with several drug targets that have potential implications for the treatment of these diseases.

What does KIAA1217 do?

KIAA1217 is a transcription factor that regulates gene expression during the cell cycle. Studies have shown that KIAA1217 has higher expression levels in cells in the G1 and G2 phases, while lower expression levels in cells in the S and G0 phases. This suggests that KIAA1217 plays different roles in different stages of the cell cycle.

In addition, studies have shown that KIAA1217 is also involved in some important biological processes, including cell proliferation, apoptosis and cell differentiation. For example, studies have shown that KIAA1217 plays an important role in tumorigenesis and cell cycle regulation. In addition, KIAA1217 also interacts with some important proteins, including histones, p21 and p53.

Pharmacological significance of KIAA1217

KIAA1217 is considered a potential drug target due to its role in many diseases. First, studies have shown that activation of KIAA1217 can lead to cell proliferation and apoptosis, therefore, inhibitors of KIAA1217 can inhibit tumor growth. In addition, activation of KIAA1217 may also lead to cell cycle arrest. Therefore, inhibitors of KIAA1217 may also inhibit the proliferation of cancer cells.

Secondly, studies have shown that activation of KIAA1217 is related to the occurrence and development of some diseases. For example, studies have shown that activation of KIAA1217 is associated with neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. In addition, activation of KIAA1217 is also associated with liver diseases, such as liver

Protein Name: KIAA1217

Functions: Required for normal development of intervertebral disks

The "KIAA1217 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIAA1217 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets